Tolebrutinib

Tolebrutinib
Clinical data
Other names	PRN2246; SAR-442168
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one;
CAS Number	1971920-73-6;
PubChem CID	124111565;
DrugBank	DB18715;
ChemSpider	88298633;
UNII	8CZ82ZYY9X;
KEGG	D12213;
ChEMBL	ChEMBL4650323;
Chemical and physical data
Formula	C26H25N5O3
Molar mass	455.518 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5;
	InChI InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1; Key:KOEUOFPEZFUWRF-LJQANCHMSA-N;

Tolebrutinib is an investigational new drug that is being evaluated to treat multiple sclerosis.^[1] It is a Bruton's tyrosine kinase (BTK) inhibitor.^[2]

References